Chung Wu Investment Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Chung Wu Investment Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30	Closed	-$23.2K	–	298
2026 Q1	$23.2K	Hold	30	–	–	0.02%	163
2025 Q4	$23.2K	Hold	30	–	–	0.02%	170
2025 Q3	$16.9K	Hold	30	–	–	0.01%	186
2025 Q2	$15.8K	Buy	+30	New	+$16.7K	0.02%	177

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Chung Wu Investment Group's REGN Position: Q2 2026 in Review

Chung Wu Investment Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 30 shares — an estimated $23.2K sold.

Chung Wu Investment Group first reported a position in REGN in Q2 2025 and held it in 4 quarters. The position peaked at $23.2K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Chung Wu Investment Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Chung Wu Investment Group sold 30 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $23.2K.
Chung Wu Investment Group first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Chung Wu Investment Group's Regeneron Pharmaceuticals position peaked at $23.2K in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Chung Wu Investment Group's 13F filing for Q2 2026, filed 31 Jul 2026.